Selected article for: "disease early diagnosis and treatment diagnosis"
Author: Pingping Zhang; Qi Gao; Tang Wang; Yuehua Ke; Fei Mo; Ruizhong Jia; Wanbing Liu; Lei Liu; Shangen Zheng; Yuzhen Liu; Luping Li; Yao Wang; Lei Xu; Kun Hao; Ruifu Yang; Shiyue Li; Changqing Lin; Yong Zhao
Title: Evaluation of recombinant nucleocapsid and spike proteins for serological diagnosis of novel coronavirus disease 2019 (COVID-19)
  • Document date: 2020_3_20
    • ID: 7atoko6c_2
    Snippet: Committee on Taxonomy of Viruses) [1] . However, this name is prone to confusion 7 with SARS-CoV, which emerged in 2003, and a suggestion for a distinct name was 8 proposed, human coronavirus 2019 (HCoV-19) [2] . This novel virus is potentially 9 more transmissible than SARS-CoV and other coronavirus [3], making early 10 diagnosis of it important for clinical treatment and disease control. However, the 11 current nucleic acid testing approach for.....
    Document: Committee on Taxonomy of Viruses) [1] . However, this name is prone to confusion 7 with SARS-CoV, which emerged in 2003, and a suggestion for a distinct name was 8 proposed, human coronavirus 2019 (HCoV-19) [2] . This novel virus is potentially 9 more transmissible than SARS-CoV and other coronavirus [3], making early 10 diagnosis of it important for clinical treatment and disease control. However, the 11 current nucleic acid testing approach for HCoV-19 [4] carries a negligible 12 false-negative risk [5] . Serological assays are supposedly a powerful approach for 13 achieving timely diagnosis of COVID-19, as is nucleic acid testing, especially for 14 patients with undetectable viral RNA [6] . The serological assays used for early 15 diagnosis are mainly based on detecting specific antibodies against HCoV-19 in a 16 patient's serum and include the enzyme-linked immunosorbent assay (ELISA), the 17 colloidal gold immunochromatography assay (GICA) and the chemiluminescence 18 assay. 19

    Search related documents:
    Co phrase search for related documents
    • clinical treatment and disease control: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • clinical treatment and disease control clinical treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • clinical treatment and ELISA immunosorbent assay: 1, 2, 3, 4, 5, 6, 7, 8
    • clinical treatment and immunosorbent assay: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • clinical treatment and novel virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • clinical treatment and nucleic acid testing: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • clinical treatment and serological assay: 1, 2
    • clinical treatment and specific antibody: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • clinical treatment and specific antibody detect: 1
    • clinical treatment and testing approach: 1, 2
    • clinical treatment and timely diagnosis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • clinical treatment and timely diagnosis achieve: 1
    • colloidal gold and ELISA immunosorbent assay: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • colloidal gold and immunosorbent assay: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • colloidal gold and nucleic acid testing: 1, 2
    • colloidal gold and serological assay: 1, 2, 3, 4
    • colloidal gold and specific antibody: 1, 2, 3, 4, 5
    • colloidal gold and specific antibody detect: 1
    • colloidal gold and timely diagnosis: 1